Matching Items (4)
Filtering by
- All Subjects: Cancer
Description
Cancer is the second leading cause of death in the United States and novel methods of treating advanced malignancies are of high importance. Of these deaths, prostate cancer and breast cancer are the second most fatal carcinomas in men and women respectively, while pancreatic cancer is the fourth most fatal in both men and women. Developing new drugs for the treatment of cancer is both a slow and expensive process. It is estimated that it takes an average of 15 years and an expense of $800 million to bring a single new drug to the market. However, it is also estimated that nearly 40% of that cost could be avoided by finding alternative uses for drugs that have already been approved by the Food and Drug Administration (FDA). The research presented in this document describes the testing, identification, and mechanistic evaluation of novel methods for treating many human carcinomas using drugs previously approved by the FDA. A tissue culture plate-based screening of FDA approved drugs will identify compounds that can be used in combination with the protein TRAIL to induce apoptosis selectively in cancer cells. Identified leads will next be optimized using high-throughput microfluidic devices to determine the most effective treatment conditions. Finally, a rigorous mechanistic analysis will be conducted to understand how the FDA-approved drug mitoxantrone, sensitizes cancer cells to TRAIL-mediated apoptosis.
ContributorsTaylor, David (Author) / Rege, Kaushal (Thesis advisor) / Jayaraman, Arul (Committee member) / Nielsen, David (Committee member) / Kodibagkar, Vikram (Committee member) / Dai, Lenore (Committee member) / Arizona State University (Publisher)
Created2013
Description
In a dormant state, cancer cells survive chemotherapy leaving the opportunity for cancer cell relapse and metastasis ultimately leading to patient death. A novel aminoglycoside-based hydrogel ‘Amikagel’ developed in Dr. Rege’s lab serves as a platform for a 3D tumor microenvironment (3DTM) mimicking cancer cell dormancy and relapse. Six Amikagels of varying mechanical stiffness and adhesivities were synthesized and evaluated as platforms for 3DTM formation through cell viability and cell cycle arrest analyses. The impact of fetal bovine serum concentration and bovine serum albumin concentration in the media were studied for their impact on 3DTM formation. These experiments allow us to identify the best possible Amikagel formulation for 3DTM.
ContributorsGjertsen, Haley Nicole (Author) / Rege, Kaushal (Thesis director) / Grandhi, Taraka Sai Pavan (Committee member) / Chemical Engineering Program (Contributor) / Barrett, The Honors College (Contributor)
Created2016-05
Description
Abstract Molecular Engineering of Novel Polymeric Agents for Targeted Cancer Gene Therapy Dana Matthews Cancer gene cell therapy is a strategy that involves the administration of genes for correcting the effect of mutated cancer cells in order to induce tumor cell death. In particular, genes that encode for pro-apoptotic proteins can result in death of tumor cells. Prostate cancer is a very common cancer among males in America, and as highly destructive chemotherapy and radiation are generally the only treatments available once the cancer has metastasized, there is a need for the development of treatments that can specifically target and kill prostate cancer cells, while demonstrating low toxicity to other tissue. This experiment will attempt to create such a treatment through gene therapy techniques. The parallel synthesis and DNA binding affinity assay utilized in these experiments have produced a polymer that surpasses pEI-25, a gene delivery polymer standard, in both transfection efficacy and low cytotoxicity and trafficking of polyplexes in the cell, and finding methods to increase the transfection efficacy and specificity of polyplexes for PC3-PSMA cells.
ContributorsMatthews, Dana (Author) / Rege, Kaushal (Thesis director) / Linton, Rebecca (Committee member) / Huang, Huang-Chial (Committee member) / Barrett, The Honors College (Contributor)
Created2008-12
Description
The use of mRNA for therapeutic purposes has gained significant attention due to its potential to treat a wide range of diseases, including cancer, infectious diseases, and genetic disorders. However, the efficient delivery of mRNA to target cells remains a major challenge, and delivery of mRNA faces major issues such as rapid degradation and poor cellular uptake. Aminoglycoside-derived lipopolymer nanoparticles (LPNs) have been shown as a promising platform for plasmid DNA (pDNA) delivery due to their stability, biocompatibility, and ability to encapsulate mRNA. The current study aims to develop and optimize LPNs formulation for the delivery of mRNA in aggressive cancer cells, using a combination of chemical synthesis, physicochemical characterization, and in vitro biological assays. From a small library of aminoglycoside-derived lipopolymers, the lead lipopolymers were screened for the efficient delivery of mRNA. The complexes were synthesized with different ratios of lipopolymers to mRNA. The appropriate binding ratios of lipopolymers and mRNA were determined by gel electrophoresis. The complexes were characterized using dynamic light scattering (DLS) and zeta potential. The transgene expression efficacy of polymers was evaluated using in vitro bioluminescence assay. The toxicity of LPNs and LPNs-mRNA complexes was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The current study comprehensively investigates the optimization of the LPNs-mRNA formulation for enhanced efficacy in transgene expression in human advanced-stage melanoma cell lines.
ContributorsWubhayavedantapuram, Revanth (Author) / Rege, Kaushal (Thesis advisor) / Acharya, Abhinav (Committee member) / Yaron, Jordan (Committee member) / Arizona State University (Publisher)
Created2023